Rapid and effective haemostatic action
PeproStat is a new class of topical haemostat that is applied directly to a wound during surgery to control bleeding. PeproStat polymerises fibrinogen into a fibrin-like clot, without the need for the enzyme thrombin. This novel mode of action is rapid and effective, and the efficacy of the product has been demonstrated in numerous pre-clinical surgical haemostasis models. In a comparative trial, PeproStat was significantly faster and more effective than four current therapies. A pre-clinical safety programme is close to completion, and the Product is scheduled to enter a Phase IIa clinical trial during 2013, subject to regulatory approval.
PeproStat is being developed in a range of topical dose forms to meet varying surgical needs. The key advantage of the product is its stability in liquid form that enables the development of a greater range of ready-to-use formulations. In contrast, the current market leader, thrombin, has to be stored in lyophilised or frozen form and the product has then to be made up in the surgery prior to use. As speed and convenience are desirable in a surgical setting, and essential in trauma, PeproStat has significant competitive advantage.
PeproStat formulations in development at Haemostatix:
- liquid formulation applied with a bioresorbable gelatin sponge
- coated pad
- ready-to-use paste applied via syringe
Improved safety profile
PeproStat is based on a short peptide attached to a carrier, and offers a potentially improved safety profile compared to current brand leaders based on thrombin extracted from human or bovine blood.
A new class with a unique mode of action
PeproStat is based on the Company’s proprietary fibrinogen-binding peptide technology. Learn more about the mode of action More...